Literature DB >> 12438348

Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Olívia Bacellar1, Hélio Lessa, Albert Schriefer, Paulo Machado, Amélia Ribeiro de Jesus, Walderez O Dutra, Kenneth J Gollob, Edgar M Carvalho.   

Abstract

The cytokine profile produced by peripheral blood mononuclear cells (PBMC) in response to leishmania antigens and the ability of interleukin-10 (IL-10) and transforming growth factor beta (TGF-beta) to modulate the immune response were evaluated in 21 mucosal leishmaniasis patients. Patients with mucosal disease exhibited increased gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) secretion and decreased IL-10 secretion compared to patients with classical cutaneous leishmaniasis. CD4(+) Th1 cells were the main source of IFN-gamma and TNF-alpha production in mucosal leishmaniasis patients. Evaluation of cytokine gene expression in PBMC of these patients showed that there was strong up-regulation of IFN-gamma transcripts upon stimulation with leishmania antigen, in contrast to the baseline levels of IL-10 mRNA. IL-10 suppressed IFN-gamma production by 48% in cell cultures from cutaneous leishmaniasis patients and by 86% in cell cultures from healthy subjects stimulated with purified protein derivative, whereas in similar conditions IL-10 suppressed IFN-gamma production by 19% in cell cultures from mucosal leishmaniasis patients stimulated with leishmania antigen. TGF-beta suppressed IFN-gamma levels to a greater extent in healthy subjects than in mucosal leishmaniasis and cutaneous leishmaniasis patients. These data indicate that a poorly modulated T-cell response in mucosal leishmaniasis patients leads to production of high levels of proinflammatory cytokines, such as IFN-gamma and TNF-alpha, as well as a decreased ability of IL-10 and TGF-beta to modulate this response. These abnormalities may be the basis for the pathological findings observed in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438348      PMCID: PMC132996          DOI: 10.1128/IAI.70.12.6734-6740.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data.

Authors:  G E Grau; P F Piguet; P Vassalli; P H Lambert
Journal:  Immunol Rev       Date:  1989-12       Impact factor: 12.988

2.  Interaction of Mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10.

Authors:  C Othieno; C S Hirsch; B D Hamilton; K Wilkinson; J J Ellner; Z Toossi
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.

Authors:  R L Bottrel; W O Dutra; F A Martins; B Gontijo; E Carvalho; M Barral-Netto; A Barral; R P Almeida; W Mayrink; R Locksley; K J Gollob
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.

Authors:  H A Lessa; P Machado; F Lima; A A Cruz; O Bacellar; J Guerreiro; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

5.  Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis.

Authors:  M Castés; A Agnelli; A J Rondón
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

6.  Cell mediated immunity in American cutaneous and mucosal leishmaniasis.

Authors:  E M Carvalho; W D Johnson; E Barreto; P D Marsden; J L Costa; S Reed; H Rocha
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

7.  Identification of human stocks of Leishmania spp. isolated from patients with mucocutaneous leishmaniasis in Três Braços, Bahia, Brazil.

Authors:  C A Cuba Cuba; P D Marsden; A C Barreto; I Roitman; A Vexenat; L M de Lima; M H de Sá
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

8.  Expression cloning and characterization of a human IL-10 receptor.

Authors:  Y Liu; S H Wei; A S Ho; R de Waal Malefyt; K W Moore
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

9.  Characterization of the cellular immune response in American cutaneous leishmaniasis.

Authors:  M Castes; A Agnelli; O Verde; A J Rondón
Journal:  Clin Immunol Immunopathol       Date:  1983-05

10.  Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.

Authors:  E M Carvalho; O Bacellar; A Barral; R Badaro; W D Johnson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

View more
  156 in total

1.  FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  L Castellucci; S E Jamieson; E N Miller; L F de Almeida; J Oliveira; A Magalhães; L H Guimarães; M Lessa; E Lago; A R de Jesus; E M Carvalho; J M Blackwell
Journal:  Genes Immun       Date:  2011-06-02       Impact factor: 2.676

2.  Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis.

Authors:  Carolina Gallego; Douglas Golenbock; Maria Adelaida Gomez; Nancy Gore Saravia
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

3.  Systemic cytokine response in humans with chiclero's ulcers.

Authors:  C M Lezama-Davila; A P Isaac-Marquez
Journal:  Parasitol Res       Date:  2006-04-22       Impact factor: 2.289

4.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

5.  Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy.

Authors:  Rúbia S Costa; Lucas P Carvalho; Taís M Campos; Andréa S Magalhães; Sara T Passos; Albert Schriefer; Juliana A Silva; Ednaldo Lago; Camilla S Paixão; Paulo Machado; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

6.  Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms.

Authors:  Adriano Queiroz; Rosana Sousa; Claudia Heine; Manuela Cardoso; Luiz Henrique Guimarães; Paulo Roberto Lima Machado; Edgar M Carvalho; Lee W Riley; Mary E Wilson; Albert Schriefer
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

7.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

9.  Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis.

Authors:  A Schriefer; A L F Schriefer; A Góes-Neto; L H Guimarães; L P Carvalho; R P Almeida; P R Machado; H A Lessa; A Ribeiro de Jesus; L W Riley; E M Carvalho
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation.

Authors:  L R V Antonelli; W O Dutra; R P Almeida; O Bacellar; K J Gollob
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.